Executive view · Daniel Reyes · Q3 2026

How the organization thinks, decides, and learns

Are strategic missions moving?

3 of 4

1 stalled: DACH (evidence gap, 2 wks)

Are decisions being tested?

78%

11 of 14 decisions carry experiments

Is learning being reused?

6 reuses

across 4 missions this quarter

Mission portfolio

Mission	Health	Target	Impact
Qualified pipeline +20%	On track	61% closed	+$420K
DACH CAC reduction	Stalled	18%	—
Partner-led motion	Early	6%	—
Billing-surprise churn	Done	120%	$380K

Decision quality

Decisions missing evidence1 — DACH draft

Decisions without owners0

Unresolved objections attached2 (monitored)

Awaiting scheduled review3 — next Sep 28

Experiment system

Active experiments3

Throughput (quarter)6 concluded

Assumptions supported / rejected / inconclusive4 / 2 / 1

Execution system

Work in progress23 tasks · 2 workflows

AI agent capacity used39% of governed budget

Human approval delay (median)1.4 days · legal 5.8

Launch risks open1 blocking · Aug 4 launch

Organizational learning

Important new learningL-021 pricing transparency

Repeated failed assumption“more time = more conversion” (×2)

Cross-mission reuse6 instances

Verified business impact · YTD

Revenue & pipeline

$1.24M

Cost reduction / avoided

$310K

Time saved (approvals + agents)

~610 h

Risk prevented

2 launches stopped

All figures finance-verified with attribution confidence noted in the impact ledger.